ClinicalTrials.gg
Active, not recruitingNCT06764485rechARgeUpdated Sep 30, 2026

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 3 interventional study of BMS-986365 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer, sponsored by Celgene. Active, not recruiting at 227 sites in 26 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026First sites in Finland, Israel and Mexico15 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 1 of them phase 3. Prostatic Neoplasms · Bristol-Myers Squibb.

Planned enrollment
5th of 29
960 · median 94
Started
2025
the only one that year
Phase 3
6 of 30
none open now
Registered
29th of 30
by date

Among the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, this one is the 5th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 3, and was the 29th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Read the detailed description

The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of BMS-986365 versus investigator's choice comprising Docetaxel + Prednisone/Prednisolone or Abiraterone + Prednisone/Prednisolone or Enzalutamide.

In Part 1, participants will be randomized 1:1:1 to one of the two BMS-986365 dose levels, or to the active comparator arm (investigator's choice). In Part 2 of the study, participants will be randomized 1:1 between BMS-986365 selected dose, or to the active comparator arm (investigator's choice).

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Keywords

  • Prostate cancer
  • Protein degrader
  • Protein degradation
  • Androgen receptor
  • Castrate resistant prostate cancer
  • Castration resistant prostate cancer
  • Hormone resistant
  • Metastatic hormone resistant prostate cancer
  • Metastatic castrate resistant prostate cancer
  • Metastatic castration resistant prostate cancer
  • BMS-986365
  • CC-94676
  • CA071-1000
  • CA0711000
  • rechARge
  • Abiraterone
  • Docetaxel
  • Enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features.
  • Participants must have current evidence of disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI).
  • Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be \< 4.
  • Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).

Exclusion criteria

Exclusion Criteria

  • Participants must not have impaired cardiac function or cardiac disease.
  • Participants must not have any .
  • Participants must not have any liver .
  • Participants with superscan on technetium-99m (Tc-99m) radionuclide bone scans.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose 1

    Drug: BMS-986365

  • Experimental
    Part 1: Dose 2

    Drug: BMS-986365

  • Active comparator
    Part 1: Comparator 1

    Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone

    Drug: Enzalutamide · Drug: Abiraterone · Drug: Predinsone/Prednisolone

  • Active comparator
    Part 1: Comparator 2

    Drug: Docetaxel · Drug: Predinsone/Prednisolone

  • Experimental
    Part 2: Dose Selected

    Drug: BMS-986365

  • Active comparator
    Part 2: Comparator 1

    Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone

    Drug: Enzalutamide · Drug: Abiraterone · Drug: Predinsone/Prednisolone

  • Active comparator
    Part 2: Comparator 2

    Drug: Docetaxel · Drug: Predinsone/Prednisolone

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • DrugPredinsone/Prednisolone

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Radiographic progression-free survival (rPFS) by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteria

    Time frame: Up to 4 years

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 4 years

  2. Recommended dose of BMS-986365 for Part 2

    Time frame: Up to approximately 1.5 years

  3. Progression-free survival (PFS)

    Time frame: Up to 4 years

  4. Confirmed overall response rate (ORR) by BICR assessment in participants with measurable disease using RECIST 1.1 (soft tissue) and PCWG3 (bone) criteria

    Time frame: Up to 4 years

  5. Time to pain progression (TTPP)

    Time frame: Up to 4 years

  6. Time to symptomatic progression (TTSP)

    Time frame: Up to 4 years

  7. Time to initiation of the first subsequent systemic therapy (TFST)

    Time frame: Up to 4 years

  8. Prostate-specific antigen (PSA) response rate

    Time frame: Up to 4 years

  9. Change from baseline in Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P) total scores

    Time frame: Up to 4 years

  10. Change from baseline in Prostate Cancer Subscale (PCS) scores

    Time frame: Up to 4 years

  11. Change from baseline in trial outcome index (TOI)

    Time frame: Up to 4 years

  12. Change from baseline in Brief Pain Inventory - Short Form (BPI-SF) worst pain (item #3) intensity

    Time frame: Up to 4 years

  13. Incidence of adverse events (AEs)

    Time frame: Up to 4 years

  14. Incidence of serious adverse events (SAEs)

    Time frame: Up to 4 years

  15. Incidence of AEs leading to dose modifications

    Time frame: Up to 4 years

  16. Incidence of AEs leading to interruptions

    Time frame: Up to 4 years

  17. Incidence of AEs leading to discontinuation

    Time frame: Up to 4 years

  18. Electrocardiogram (ECG) findings

    ECG Findings defined as : * Number of Postbaseline Abnormal Corrected QT (QTc) Values * Number of abnormal Beats Per Minute (BPM)

    Time frame: Up to 4 years

  19. Incidence of laboratory abnormalities

    Time frame: Up to 4 years

07

Study locations

227 sites
  • Local Institution - 0330
    Birmingham, Alabama 35209, United States
  • Local Institution - 0329
    Gilbert, Arizona 85234, United States
  • Local Institution - 0370
    Anaheim, California 92801, United States
  • Local Institution - 0015
    La Jolla, California 92093, United States
  • Local Institution - 0224
    Los Alamitos, California 90720, United States
  • Local Institution - 0016
    San Francisco, California 94115, United States
  • Local Institution - 0411
    San Francisco, California 94121, United States
  • Local Institution - 0238
    Aurora, Colorado 80045, United States
  • Local Institution - 0294
    Denver, Colorado 80218, United States
  • Local Institution - 0419
    Lakewood, Colorado 80228, United States
  • Local Institution - 0413
    Washington D.C., District of Columbia 20016, United States
  • Local Institution - 0426
    Lakeland, Florida 33805, United States
  • Local Institution - 0077
    Athens, Georgia 30607, United States
  • Local Institution - 0048
    Chicago, Illinois 60611, United States
  • Local Institution - 0331
    Westwood, Kansas 66205, United States
  • Local Institution - 0060
    Wichita, Kansas 67226, United States
  • Local Institution - 0054
    Baltimore, Maryland 21204, United States
  • Local Institution - 0019
    Baltimore, Maryland 21287, United States
  • Local Institution - 0344
    Frederick, Maryland 21702, United States
  • Local Institution - 0429
    Sewell, New Jersey 08080, United States
  • Local Institution - 0081
    Albuquerque, New Mexico 87106, United States
  • Local Institution - 0334
    Albuquerque, New Mexico 87109, United States
  • Local Institution - 0197
    Buffalo, New York 14263, United States
  • Local Institution - 0412
    Mineola, New York 11501, United States
  • Local Institution - 0069
    New York, New York 10016, United States
  • Local Institution - 0076
    New York, New York 10029, United States
  • Local Institution - 0085
    New York, New York 10032, United States
  • Local Institution - 0071
    New York, New York 10065, United States
  • Local Institution - 0225
    Syracuse, New York 13210, United States
  • Local Institution - 0056
    Columbus, Ohio 43210, United States
  • Local Institution - 0067
    Portland, Oregon 97213, United States
  • Local Institution - 0416
    Portland, Oregon 97225, United States
  • Local Institution - 0345
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0414
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 0057
    Philadelphia, Pennsylvania 19111, United States
  • Local Institution - 0349
    Willow Grove, Pennsylvania 19090, United States
  • Local Institution - 0055
    Charleston, South Carolina 29425, United States
  • Local Institution - 0079
    Myrtle Beach, South Carolina 29572, United States
  • Local Institution - 0335
    Nashville, Tennessee 37203, United States
  • Local Institution - 0018
    Austin, Texas 78705, United States
  • Local Institution - 0114
    Austin, Texas 78745, United States
  • Local Institution - 0042
    Houston, Texas 77030, United States
  • Local Institution - 0220
    Houston, Texas 77030, United States
  • Local Institution - 0109
    Murray, Utah 84107, United States
  • Local Institution - 0050
    Charlottesville, Virginia 22903, United States
  • Local Institution - 0078
    Seattle, Washington 98109, United States
  • Local Institution - 0293
    Vancouver, Washington 98684, United States
  • Local Institution - 0112
    Milwaukee, Wisconsin 53226, United States
  • Local Institution - 0125
    CABA, Buenos Aires CP1280AEB, Argentina
  • Local Institution - 0124
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
  • Local Institution - 0128
    ABB, Buenos Aires F.D. C1199ABB, Argentina
  • Local Institution - 0235
    Córdoba, Córdoba Province X5004BAL, Argentina
  • Local Institution - 0130
    Río Cuarto, Córdoba Province X5800AEV, Argentina
  • Local Institution - 0136
    Viedma, R R8500ACE, Argentina
  • Local Institution - 0129
    Buenos Aires, C1419AHN, Argentina
  • Local Institution - 0430
    Córdoba, 5016, Argentina
  • Local Institution - 0366
    Campbelltown, New South Wales 2560, Australia
  • Local Institution - 0359
    Darlinghurst, New South Wales 2010, Australia
  • Local Institution - 0356
    Macquarie University, New South Wales 2109, Australia
  • Local Institution - 0360
    Port Macquarie, New South Wales 2444, Australia
  • Local Institution - 0355
    Wahroonga, New South Wales 2076, Australia
  • Local Institution - 0347
    Greenslopes, Queensland 4120, Australia
  • Local Institution - 0351
    Southport, Queensland 4215, Australia
  • Local Institution - 0362
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0358
    Elizabeth Vale, South Australia 5112, Australia
  • Local Institution - 0352
    Kurralta Park, South Australia 5037, Australia
  • Local Institution - 0354
    Hobart, Tasmania 7000, Australia
  • Local Institution - 0363
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0353
    Malvern, Victoria 3144, Australia
  • Local Institution - 0348
    Melbourne, Victoria 3000, Australia
  • Local Institution - 0361
    Melbourne, Victoria 3004, Australia
  • Local Institution - 0357
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0369
    Krems, Lower Austria 3500, Austria
  • Local Institution - 0373
    Linz, Upper Austria 4020, Austria
  • Local Institution - 0367
    Salzburg, 5020, Austria
  • Local Institution - 0368
    Vienna, 1090, Austria
  • Local Institution - 0025
    Belo Horizonte, Minas Gerais 30110-022, Brazil
  • Local Institution - 0035
    Natal, Rio Grande do Norte 59075-740, Brazil
  • Local Institution - 0026
    Porto Alegre, Rio Grande do Sul 90035-001, Brazil
  • Local Institution - 0395
    São Paulo, São Paulo 01308-060, Brazil
  • Local Institution - 0031
    São Paulo, São Paulo 01509-010, Brazil
  • Local Institution - 0304
    Kelowna, British Columbia V1Y 5L3, Canada
  • Local Institution - 0152
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0151
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution - 0193
    Toronto, Ontario M4N 3M5, Canada
  • Local Institution - 0093
    Chicoutimi, Quebec G7H 5H6, Canada
  • Local Institution - 0149
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0305
    Montreal, Quebec H4A 3J1, Canada
  • Local Institution - 0150
    Québec, Quebec G1J 1Z4, Canada
  • Local Institution - 0164
    Rimouski, Quebec G5L 5T1, Canada
  • Local Institution - 0236
    Valdivia, Los Ríos Region 5112129, Chile
  • Local Institution - 0135
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0132
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0127
    Viña del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0232
    Hefei, Anhui 230000, China
  • Local Institution - 0192
    Beijing, Beijing Municipality 100034, China
  • Local Institution - 0249
    Fuzhou, Fujian 350001, China
  • Local Institution - 0213
    Xiamen, Fujian 361003, China
  • Local Institution - 0226
    Guangzhou, Guangdong 510060, China
  • Local Institution - 0180
    Guangzhou, Guangdong 510180, China

Showing the first 100 of 227 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Jan;36(1):76-88. doi: 10.1016/j.annonc.2024.09.005. Epub 2024 Sep 16. PubMed 39293515 ↗
  • Nayak S, Norris JD, Ammirante M, Rychak E, Wardell SE, Liao D, Toyama B, Kandimalla R, Christoforou A, Tsuji T, Liu K, Tran M, Meiring J, Reiss S, Piccotti JR, Baughman JM, Fontanillo C, Khater M, Mortensen DS, Cathers B, Bence N, Pierce DW, Plantevin-Krenitsky V, Rathkopf D, Hansen JD, Hamann LG, Narla RK, Arora VK, McDonnell DP, Rolfe M, Xu S. Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer. Clin Cancer Res. 2026 Jan 6;32(1):224-241. doi: 10.1158/1078-0432.CCR-25-0471. PubMed 40788283 ↗
  • Chi KN, McKay RR, Sandhu S, Arranz JA, Barthelemy P, Hadaschik B, Matsubara N, Shore ND, Ye D, Cascella T, Irincheeva I, Kreiser S, Thiery-Vuillemin A, Rathkopf DE. rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. Future Oncol. 2025 Jun;21(14):1771-1777. doi: 10.1080/14796694.2025.2502318. Epub 2025 Jun 2. PubMed 40455815 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 29 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 8, 2025
StartActual
Mar 13, 2025
Primary completionEst.
Sep 12, 2027
CompletionEst.
Jan 19, 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added — first sites in Finland, Israel and Mexico
Show 15 added (6 Mexico, 5 Israel, 4 Finland)
  • Local Institution - 0096 · Kuopio, Finland
  • Local Institution - 0285 · Tampere, Finland
  • Local Institution - 0242 · Turku, Finland
  • Local Institution - 0101 · Oulu, Finland
  • Local Institution - 0206 · Kfar Saba, Israel
  • Local Institution - 0208 · Petah Tikva, Israel
  • Local Institution - 0207 · Ramat Gan, Israel
  • Local Institution - 0210 · Ẕerifin, Israel
  • Local Institution - 0209 · Haifa, Israel
  • Local Institution - 0121 · Mexico City, Mexico
  • Local Institution - 0120 · Guadalajara, Mexico
  • Local Institution - 0001 · Guadalajara, Mexico
  • Local Institution - 0002 · Monterrey, Mexico
  • Local Institution - 0122 · Chihuahua City, Mexico
  • Local Institution - 0119 · Puebla City, Mexico
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    15 sites added — first sites in Finland, Israel and Mexico
    Show 15 added (6 Mexico, 5 Israel, 4 Finland)
    • Local Institution - 0096 · Kuopio, Finland
    • Local Institution - 0285 · Tampere, Finland
    • Local Institution - 0242 · Turku, Finland
    • Local Institution - 0101 · Oulu, Finland
    • Local Institution - 0206 · Kfar Saba, Israel
    • Local Institution - 0208 · Petah Tikva, Israel
    • Local Institution - 0207 · Ramat Gan, Israel
    • Local Institution - 0210 · Ẕerifin, Israel
    • Local Institution - 0209 · Haifa, Israel
    • Local Institution - 0121 · Mexico City, Mexico
    • Local Institution - 0120 · Guadalajara, Mexico
    • Local Institution - 0001 · Guadalajara, Mexico
    • Local Institution - 0002 · Monterrey, Mexico
    • Local Institution - 0122 · Chihuahua City, Mexico
    • Local Institution - 0119 · Puebla City, Mexico

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06764485
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Mar 13, 2025
Primary completion
Sep 12, 2027 (estimated)
Completion
Jan 19, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dezandrodeg

Start the discussion